A thalidomide–hydroxyurea hybrid increases HbF production in sickle cell mice and reduces the release of proinflammatory cytokines in cultured monocytes

Akinsheye, 2011, Fetal hemoglobin in sickle cell anemia, Blood, 118, 19, 10.1182/blood-2011-03-325258 Humphries, 2014, Drug development: a complicated path, Nature, 515, S4, 10.1038/515S4a Cokic, 2003, Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase, J Clin Invest, 111, 231, 10.1172/JCI200316672 Steinberg, 1997, Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea, Blood, 89, 1078, 10.1182/blood.V89.3.1078 Charache, 1995, Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia, N Engl J Med, 332, 1317, 10.1056/NEJM199505183322001 Aerbajinai, 2007, Thalidomide induces γ-globin gene expression through increased reactive oxygen species–mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis, Blood, 110, 2864, 10.1182/blood-2007-01-065201 Moutouh-de Parseval, 2008, Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells, J Clin Invest, 118, 248, 10.1172/JCI32322 Meiler, 2011, Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice, Blood, 118, 1109, 10.1182/blood-2010-11-319137 Dulmovits, 2016, Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors, Blood, 127, 1481, 10.1182/blood-2015-09-667923 dos Santos, 2011, Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms, J Med Chem, 54, 5811, 10.1021/jm200531f Silva, 2016, Beneficial effect of the nitric oxide donor compound 3-(1,3-dioxoisoindolin-2-yl)benzyl nitrate on dysregulated phosphodiesterase 5, NADPH oxidase and nitrosative stress in the sickle cell mouse penis: implication for priapism treatment, J Pharmacol Exp Ther, 359, 230, 10.1124/jpet.116.235473 Ryan, 1997, Knockout-transgenic mouse model of sickle cell disease, Science, 278, 873, 10.1126/science.278.5339.873 Manwani, 2013, Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies, Blood, 122, 3892, 10.1182/blood-2013-05-498311 Shannon, 2007, Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia, Transl Res, 150, 275, 10.1016/j.trsl.2007.05.003 Shannon, 2008, Thalidomide suppressed IL-1beta while enhancing TNF-alpha and IL-10, when cells in whole blood were stimulated with lipopolysaccharide, Immunopharmacol Immunotoxicol, 30, 447, 10.1080/08923970802135161 Godin, 2014, Activities of 2-phthalimidethanol and 2-phthalimidethyl nitrate, phthalimide analogs devoid of the glutarimide moiety, in experimental models of inflammatory pain and edema, Pharmacol Biochem Behav, 122, 291, 10.1016/j.pbb.2014.04.008 Lanaro, 2009, Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy, J Leukoc Biol, 85, 235, 10.1189/jlb.0708445 Pitanga, 2016, Sickle red cells as danger signals on proinflammatory gene expression, leukotriene B4 and interleukin-1 beta production in peripheral blood mononuclear cell, Cytokine, 83, 75, 10.1016/j.cyto.2016.03.016 Sarray, 2015, Serum IL-6, IL-10, and TNFα levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition, Cytokine, 72, 43, 10.1016/j.cyto.2014.11.030 Jang, 2011, CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso-occlusion during hemolytic transfusion reactions, J Clin Invest, 121, 1397, 10.1172/JCI45336 Lopez-Millan, 2017, Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease, Exp Mol Med, 49, e290, 10.1038/emm.2016.143 Navarra, 1997, Hydroxyurea induces the gene expression and synthesis of proinflammatory cytokines in vivo, J Pharmacol Exp Ther, 280, 477 Tavakkoli, 2004, Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea, Hematology, 9, 61, 10.1080/1024533032000158869 Laurance, 2010, Hydroxycarbamide stimulates the production of proinflammatory cytokines by endothelial cells: relevance to sickle cell disease, Pharmacogenet Genomics, 20, 257, 10.1097/FPC.0b013e32833854d6